Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease

Journal of Pharmaceutical and Biomedical Analysis

Volumn 107, Issue , 2015, Pages 75-81

  González Domínguez, Raúl ^a   García Barrera, Tamara ^a   Gómez Ariza, José Luis ^a  

^a UNIVERSITY OF HUELVA   (Spain)

Author keywords

Alzheimer's disease; Gas chromatography mass spectrometry; Metabolomic profiling; Pathology

Indexed keywords

2 OXOGLUTARIC ACID; ADENOSINE; ASPARAGINE; ASPARTIC ACID; CHOLESTEROL; CYSTINE; GLUCOSE; GLUTAMINE; HISTIDINE; ISOCITRIC ACID; LACTIC ACID; ORNITHINE; PALMITIC ACID; PHENYLALANINE; PIPECOLIC ACID; PYROGLUTAMIC ACID; STEARIC ACID; TRYPTOPHAN; TYROSINE; UREA; URIC ACID; VALINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERIVATIZATION; FEMALE; HUMAN; HYPERAMMONEMIA; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; OXIDATIVE STRESS; PRIORITY JOURNAL; CASE CONTROL STUDY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERAMMONEMIA; MALE; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; OXIDATIVE STRESS;

EID: 84921289064     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.10.010     Document Type: Article

References (64)

1. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diagn. 2004, 4:189-199.
2. Beecher C.W.W. The human metabolome. Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis 2003, Springer, New York. G.G. Harrigan, R. Goodacre (Eds.).
3. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 2007, 26:51-78.
4. Griffin J.L. Metabonomics NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 2003, 7:648-654.
5. Ellis D.I., Goodacre R. Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst 2006, 131:875-885.
6. Dunn W.B. Current trends and future requirements for the mass spectrometric investigation of microbial, mammalian and plant metabolomes. Phys. Biol. 2008, 5:011001.
7. Fiehn O., Kopka J., Dörmann P., Altmann T., Trethewey R.N., Willmitzer L. Metabolite profiling for plant functional genomics. Nat. Biotechnol. 2000, 18:1157-1161.
8. Pasikanti K.K., Ho P.C., Chan E.C.Y. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J. Chromatogr. B 2008, 871:202-211.
9. Koek M.M., Jellema R.H., van der Greef J., Tas A.C., Hankemeier T. Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. Metabolomics 2011, 7:307-328.
10. Kopka J. Current challenges and developments in GC-MS based metabolite profiling technology. J. Biotechnol. 2006, 124:312-322.
11. Michell A.M., Mosedale D., Grainger D.J., Barker R.A. Metabolomic analysis of urine and serum in Parkinson's disease. Metabolomics 2008, 4:191-201.
12. Nishiumi S., Shinohara M., Ikeda A., Yoshie T., Hatano N., Kakuyama S., Mizuno S., Sanuki T., Kutsumi H., Fukusaki E., Azuma T., Takenawa T., Yoshida M. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics 2010, 6:518-528.
13. Hori S., Nishiumi S., Kobayashi K., Shinohara M., Hatakeyama Y., Kotani Y., Hatano N., Maniwa Y., Nishio W., Bamba T., Fukusaki E., Azuma T., Takenawa T., Nishimura Y., Yoshida M. A metabolomic approach to lung cancer. Lung Cancer 2011, 74:284-292.
14. Akesson L., Trygg J., Fuller J.M., Madsen R., Gabrielsson J., Bruce S., Stenlund H., Tupling T., Pefley R., Lundstedt T., Lernmark A., Moritz T. Serum metabolite signature predicts the acute onset of diabetes in spontaneously diabetic congenic BB rats. Metabolomics 2011, 7:593-603.
15. Underwood B.R., Broadhurst D., Dunn W.B., Ellis D.I., Michell A.W., Vacher C., Mosedale D.E., Kell D.B., Barker R.A., Grainger D.J., Rubinsztein D.C. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006, 129:877-886.
16. Czech C., Berndt P., Busch K., Schmitz O., Wiemer J., Most V., Hampel H., Kastler J., Senn H. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLOS ONE 2012, 7:e31501.
17. McKahnn G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
18. Fisher G., Lorenzo N., Abe H., Fujita E., Frey W.H., Emory C., Di Fiore M.M., D'Aniello A. Free d- and l-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. Amino Acids 1998, 15:263-269.
19. Fraser T., Tayler H., Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem. Res. 2010, 35:503-513.
20. Storga D., Vrecko K., Birkmayer J.G.D., Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci. Lett. 1996, 203:29-32.
21. Gonzalez-Dominguez R., Garcia-Barrera T., Gomez-Ariza J.L. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. J. Proteomics 2014, 104:37-47.
22. Begley P., Francis-McIntyre S., Dunn W.B., Broadhurst D.I., Halsall A., Tseng A., Knowles J., Consortium H.U.S.E.R.M.E.T., Goodacre R., Kell D.B. Development and performance of a gas chromatography-time-of-flight mass spectrometry analysis for large-scale nontargeted metabolomic studies of human serum. Anal. Chem. 2009, 81:7038-7046.
23. Katajamaa M., Oresic M. Data processing for mass spectrometry-based metabolomics. J. Chromatogr. A 2007, 1158:318-328.
24. Smith C.A., Want E.J., O'Maille G., Abagyan R., Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 2006, 78:779-787.
25. Veselkov K.A., Vingara L.K., Masson P., Robinette S.L., Want E., Li J.V., Barton R.H., Boursier-Neyret C., Walther B., Ebbels T.M., Pelczer I., Holmes E., Lindon J.C., Nicholson J.K. Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal. Chem. 2011, 83:5864-5872.
26. van den Berg R.A., Hoefsloot H.C.J., Westerhuis J.A., Smilde A.K., van der Werf M.J. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 2006, 7:142.
27. Xia J., Wishart D.S. MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics 2010, 26:2342-2344.
28. González-Domínguez R., Garcia-Barrera T., Gomez-Ariza.J.L. Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer's disease. Talanta 2015, 131:480-489.
29. Mosconi L., Mistur R., Switalski R., Tsui W.H., Glodzik L., Li Y., Pirraglia E., De Santi S., Reisberg B., Wisniewski T., de Leon M.J. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:811-822.
30. Parnetti L., Gaiti A., Polidori M.C., Brunetti M., Palumbo B., Chionne F., Cadini D., Cecchetti R., Senin U. Increased cerebrospinal fluid pyruvate levels in Alzheimer's disease. Neurosci. Lett. 1995, 199:231-233.
31. Maruszak A., Zekanowski C. Mitochondrial dysfunction and Alzheimer's disease. Prog. Neuro-Psychopharmacol. 2011, 35:320-330.
32. Bubber P., Haroutunian V., Fisch G., Blass J.P., Gibson G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 2005, 57:695-703.
33. Redjems-Bennani N., Jeandel C., Lefebvre E., Blain H., Vidailhet M., Guéanta J.L. Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology 1998, 44:300-304.
34. Fonteh A.N., Harrington R.J., Tsai A., Liao P., Harrington M.G. Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids 2007, 32:213-224.
35. Arai H., Kobayashi K., Ichimiya Y., Kosaka K., Iizuka R. A preliminary study of free amino acids in the postmorten temporal cortex from Alzheimer-type dementia patients. Neurobiol. Aging 1984, 5:319-321.
36. Fekkes D., van der Cammen T.J.M., van Loon C.P.M., Verschoor C., van Harskamp F., de Koning I., Schudel W.J., Pepplinkhuizen L. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J. Neural Transm. 1998, 105:287-294.
37. Gomes C.V., Kaster M.P., Tomé A.R., Agostinho P.M., Cunha R.A. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim. Biophys. Acta 2011, 1808:1380-1399.
38. Albasanz J.L., Perez S., Barrachina M., Ferrer I., Martín M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol. 2008, 18:211-219.
39. Angulo E., Casadó V., Mallol J., Canela E.I., Viñals F., Ferrer I., Lluis C., Franco R. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer's disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 2003, 13:440-451.
40. Kovács Z., Juhász G., Dobolyi A., Bobest M., Papp V., Takáts L., Kékesi K.A. Gender- and age-dependent changes in nucleoside levels in the cerebral cortex and white matter of the human brain. Brain Res. Bull. 2010, 81:579-584.
41. Gulaj E., Pawlak K., Bien B., Pawlak D. Kynurenine and its metabolites in Alzheimer's disease patients. Adv. Med. Sci. 2010, 55:204-211.
42. Chen C., Alder J.T., Bowen D.M., Esiri M.M., McDonald B., Hope T., Jobst K.A., Francis P.T. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. Neurochemistry 1996, 66:1592-1598.
43. Widner B., Leblhuber F., Walli J., Tilz G.P., Demel U., Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural Transm. 2000, 107:343-353.
44. Tohgi H., Abe T., Takahashi S., Kimura M., Takahashi J., Kikuchi T. Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci. Lett. 1992, 141:9-12.
45. Lin A.P., Shic F., Enriquez C., Ross B.D. Reduced glutamate neurotransmission in patients with Alzheimer's disease - an in vivo 13C magnetic resonance spectroscopy study. MAGMA 2003, 16:29-42.
46. Devore E.E., Grodstein F., van Rooij F.J.A., Hofman A., Rosner B., Stampfer M.J., Witteman J.C.M., Breteler M.M.B. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am. J. Clin. Nutr. 2009, 90:170-176.
47. Wilson D.M., Bindert L.I. Free fatty acids stimulate the polymerization of tau and amyloid β peptides. Am. J. Pathol. 1997, 150:2181-2195.
48. Wang D.C., Sun C.H., Liu L.Y., Sun X.H., Jin X.W., Song W.L., Liu X.Q., Wan X.L. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. Neurobiol. Aging 2012, 33:1057-1066.
49. Cunnane S.C., Schneider J.A., Tangney C., Tremblay-Mercier J., Fortier M., Bennett D.A., Morris M.C. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 2012, 29:691-697.
50. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6460-6464.
51. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J. Neuroinflamm. 2011, 8:26.
52. Natelson S., Sherwin J.E. Proposed mechanism for urea nitrogen re-utilization: relationship between urea and proposed guanidine cycles. Clin. Chem. 1979, 25:1343-1344.
53. Felipo V., Butterworth R.F. Neurobiology of ammonia. Prog. Neurobiol. 2002, 67:259-279.
54. Hansmannel F., Sillaire A., Kamboh M.I., Lendon C., Pasquier F., Hannequin D., Laumet G., Mounier A., Ayral A.M., DeKosky S.T., Hauw J.J., Berr C., Mann D., Amouyel P., Campion D., Lambert J.C. Is the urea cycle involved in Alzheimer's disease?. J. Alzheimers Dis. 2010, 21:1013-1021.
55. Bernstein H.G., Muller M. Increased immunostaining for l-ornithine decarboxylase occurs in neocortical neurons of Alzheimers-disease patients. Neurosci. Lett. 1995, 186:123-126.
56. Lee W.J., Hawkins R.A., Peterson D.R., Viña J.R. Role of oxoproline in the regulation of neutral amino acid transport across the blood-brain barrier. J. Biol. Chem. 1996, 271:19129-19133.
57. +-dependent glutamate transport across the blood-brain barrier. FEBS Lett. 2006, 580:4382-4386.
58. Zhu Y., Carvey P.M., Ling Z. Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res. 2006, 1090:35-44.
59. Migliore L., Fontana I., Colognato R., Coppede F., Siciliano G., Murri L. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol. Aging 2005, 26:587-595.
60. Kim T.S., Pae C.U., Yoon S.J., Jang W.Y., Lee N.J., Kim J.J., Lee S.J., Lee C., Paik I.H., Lee C.U. Decreased plasma antioxidants in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 2006, 21:344-348.
61. Wu G., Fang Y.Z., Yang S., Lupton J.R., Turner N.D. Glutathione metabolism and its implications for health. J. Nutr. 2004, 134:489-492.
62. Astarita G., Jung K.M., Berchtold N.C., Nguyen V.Q., Gillen D.L., Head E., Cotman C.W., Piomelli D. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS ONE 2010, 5:e12538.
63. Goodenowe D.B., Cook L.L., Liu J., Lu Y., Jayasinghe D.A., Ahiahonu P.W.K., Heath D., Yamazaki Y., Flax J., Krenitsky K.F., Sparks D.L., Lerner A., Friedland R.P., Kudo T., Kamino K., Morihara T., Takeda M., Wood P.L. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 2007, 48:2485-2498.
64. Cusick P.K., Koehler K.M., Ferrier B., Haskell B.E. The neurotoxicity of valine deficiency in rats. J. Nutr. 1978, 108:1200-1206.